Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: Inclusion criteria and study design

Journal of Rheumatology

Volumn 38, Issue 10, 2011, Pages 2095-2104

  Karsh, Jacob ^a,b   Keystone, Edward C ^c,d   Haraoui, Boulos ^e   Thorne, J Carter ^f   Pope, Janet E ^g,h,i   Bykerk, Vivian P ^i,j   Maksymowych, Walter P ^k,l   Zummer, Michel ^m,n   Bensen, William G ^o   Kraishi, Majed M ^p,q  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h ST JOSEPH S HEALTH CENTRE   (Canada)

ⁱ MOUNT SINAI HOSPITAL   (United States)

^j HARVARD UNIVERSITY   (United States)

^k UNIVERSITY OF ALBERTA   (Canada)

^l ALBERTA ENVIRONMENT AND PARKS   (Canada)

^m UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁿ MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^o ST JOSEPH S HOSPITAL   (Canada)

^p MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^q Nexus Clinical Research   (Canada)

more..

Author keywords

Clinical trials; Eligibility; Methodology; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE ACETATE; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE;

ADD ON THERAPY; ARTHROPATHY; CANADA; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL STATUS; HUMAN; JOINT SWELLING; JOINT TENDERNESS; LOW DRUG DOSE; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; STUDY DESIGN;

ARTHRITIS, RHEUMATOID; CANADA; CLINICAL TRIALS AS TOPIC; HUMANS; PATIENT SELECTION; RESEARCH DESIGN;

EID: 80053478970     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110188     Document Type: Review

References (119)

1. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360:816-23.
2. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nat Rev Drug Disc 2008;7:13-4.
3. Karlberg JPE. Globalization of sponsored clinical trials. Nat Rev Drug Disc 2008;7:458.
4. Devasenapathy N, Singh K, Prabhakaran D. Conduct of clinical trials in developing countries: a perspective. Curr Opin Cardiol 2009;24:295-300.
5. Stough WG, Zannad F, Pitt B, Goldstein S. Globalization of cardiovascular clinical research: the balance between meeting medical needs and maintaining scientific standards. Am Heart J 2007;154:232-8. (Pubitemid 47069136)
6. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
7. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
8. Emery P, Rigby WFC, Tak PP, Dorner T, Olech E, Genovese MC, et al. Serious infections with ocrelizumab in rheumatoid arthritis: Pooled results from double-blind periods of the ocrelizumab Phase III RA Program [abstract]. Arthritis Rheum 2010;62 Suppl:414.
9. Mody GM, Cardiel MH. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol 2008;22:621-41.
10. Brooks PM. The burden of musculoskeletal disease - a global perspective. Clin Rheumatol 2006;25:778-81. (Pubitemid 44473138)
11. Darmawan J. Recommendations from the Community Oriented Program for Control of Rheumatic Disease for data collection for the measurement and monitoring of health in developing countries. Clin Rheumatol 2007;26:853-7. (Pubitemid 46951277)
12. Woolf AD, Brooks P, Akesson K, Mody GM. Prevention of musculoskeletal conditions in the developing world. Best Pract Res Clin Rheumatol 2008;22:759-72.
13. Massardo L, Suárez-Almazor ME, Cardiel MH, Nava A, Levy RA, Laurindo I, et al. Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide. J Clin Rheumatol 2009;15:203-10.
14. Sokka T, Kautiainen H, Pincus T, Toloza S, Da Rocha Castelar Pinheiro G, Lazovskis J, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009;68:1666-72.
15. Young RC. Cancer clinical trials - a chronic but curable crisis. N Engl J Med 2010;363:306-9.
16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for good clinical practice E6 (R1). ICH harmonised tripartite guideline, 1996. ICH, Geneva, Switzerland.
17. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74:979-83. (Pubitemid 14059576)
18. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Meth 2005;8:19-32. (Pubitemid 40322704)
19. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
20. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40. (Pubitemid 26036375)
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
22. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
23. Bykerk VP, Boire G, Haraoui B, Hitchon CA, Keystone EC, Thorne JC, et al. The Revised 2010 ACR/EULAR Diagnostic Criteria for Rheumatoid Arthritis identify many more patients who are eligible for treatment and for clinical trials [abstract]. Arthritis Rheum 2010;62 Suppl:S274.
24. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
25. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
26. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374:459-66.
27. Landewé RB, Houbiers JG, van den Bosch F, in't Hout J, Verschueren PC, Meijerink JH, et al. Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. Ann Rheum Dis 2010;69:1655-9.
28. Kingsley GH, Khoshaba B, Smith CM, Choy EH, Scott DL. Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria. Rheumatology 2005;44:629-32. (Pubitemid 41487232)
29. Pincus T, Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009;35:731-4, vi-vii.
30. Abelson B, Sokka T, Pincus T. Declines in erythrocyte sedimentation rates in patients with rheumatoid arthritis over the second half of the 20th century. J Rheumatol 2009;36:1596-9.
31. Wolfe F. The many myths of erythrocyte sedimentation rate and C-reactive protein. J Rheumatol 2009;36:1568-9.
32. Wolfe F, Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. J Rheumatol 2001;28:1817-24. (Pubitemid 32726928)
33. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12.
34. Wells GA, Boers M, Li T, Tugwell PS. Investigating the validity of the minimal disease activity state for patients with rheumatoid arthritis treated with abatacept. J Rheumatol 2009;36:260-5.
35. Hensor EM, Emery P, Bingham SJ, Conaghan PG. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): Can they be reduced? Rheumatology 2010;49:1521-9.
36. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
37. Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-6.
38. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76. (Pubitemid 46768126)
39. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
40. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology 2011;50:437-49.
41. Patel AM, Moreland LW. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 2010;4:263-78.
42. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
43. Genovese MC, McKay JD, Nasonov EL, Mysler EF, Da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
44. Fleischmann R, Burgos-Vargas R, Ambs P, Alecock E, Kremer J. LITHE: Tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis (RA) patients (pts) at 2 yrs with increasing clinical efficacy over time [abstract]. Arthritis Rheum 2009;60 Suppl:637.
45. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9.
46. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
47. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
48. Pincus T, Sokka T, Chung CP, Cawkwell G. Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials. Ann Rheum Dis 2006;65:878-83.
49. Akhavan P, Bykerk V, Sun Y, Boire G, Pope J, Haraoui B, et al. "Liberal" (easier to achieve) compared to "standard" entry criteria improves trial recruitment in a real world practice. Results from the Canadian Early Rheumatoid Arthritis Cohort (CATCH) [abstract]. London: EULAR Scientific Programme. EULAR 2011: SAT0390.
50. Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington T, et al. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med 2008;121:532-8. (Pubitemid 351694340)
51. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38-43.
52. Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 2009;61:979-87.
53. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
54. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-28.
55. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
56. Zhang B, Lavalley M, Felson DT. The sensitivity to change for lower disease activity is greater than for higher disease activity in rheumatoid arthritis trials. Ann Rheum Dis 2009;68:1255-9.
57. U.S. Department of Health and Human Services. Clinical development programs for drugs, devices and biological products for the treatment of rheumatoid arthritis (RA). Washington, DC: Food and Drug Administration Center for Drug Evaluation and Research; Arthritis Advisory Committee; Guidance for Industry; volume II. February 1997.
58. Sokka T. How should rheumatoid arthritis disease activity be measured today and in the future in clinical care? Rheum Dis Clin North Am 2010;36:243-57.
59. Pincus T. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 2008;66:216-23.
60. Bell MJ, Lineker SC, Wilkins AL, Goldsmith CH, Badley EM. A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis. J Rheumatol 1998;25:231-7. (Pubitemid 28088248)
61. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
62. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:659-62.
63. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-44.
64. Crilly MA, Macdonald AG, Williams DJ, Kumar V, Clark HJ. Constitutional symptoms at the onset of rheumatoid arthritis and subsequent arterial stiffness. Clin Rheumatol 2010;29:1113-9.
65. Hayashibara M, Hagino H, Katagiri H, Okano T, Okada J, Teshima R. Incidence and risk factors of falling in ambulatory patients with rheumatoid arthritis: a prospective 1-year study. Osteoporos Int 2010;21:1825-33.
66. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
67. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35.
68. Keystone E, van der Heijde D, Mason D Jr, Landewé R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
69. Østergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010;62:2227-38.
70. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-41.
71. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11.
72. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
73. Schwieterman WD. Issues in the design of new clinical trials for rheumatoid arthritis therapeutics. Nat Clin Pract Rheumatol 2008;4:641-8.
74. Strand V, Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Res Ther 2009;11:205.
75. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009;68:1094-9.
76. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
77. National Institute for Health and Clinical Excellence (NICE). Rheumatoid arthritis: The management of rheumatoid arthritis in adults. London: National Collaborating Centre for Chronic Conditions; NICE clinical guideline 79. February 2009.
78. Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology 2009;48:436-9.
79. Bykerk V, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease modifying anti-rheumatic drugs. J Rheumatol 2011 [in press].
80. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
81. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology 2004;43:267-71. (Pubitemid 38313172)
82. Haraoui BP, Pope J, Thorne JC, Sampalis J, Psaradellis F. Regional differences between patients with rheumatoid arthritis (RA) in Canada at initiation of adalimumab treatment in Canada: Results of the Optimization of Humira Trial [abstract]. J Rheumatol 2009;36:2578.
83. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2010;4:CD008495.
84. Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 2010;49:91-8.
85. The European Agency for the Evaluation of Medicinal Products. Post-authorisation evaluation of medicines for human use. EMEA public statement on leflunomide (Arava) - severe and serious hepatic reactions. Document reference EMEA/H/5611/01/en. London: EMEA; 12 March 2001.
86. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-4.
87. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;1:CD006356.
88. Hoes JN, Jacobs JW, Buttgereit F, Bijlsma JW. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693-702.
89. Yuen SY, Pope J. Learning from past mistakes: Assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology 2008;47:1367-72.
90. Leber PD, Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 1998;19:178-87. (Pubitemid 28191972)
91. Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet 2009;374:430-2.
92. Smolen JS, Han C, Bala M, Kalden JR, van der Heijde D, Breedveld FC, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy study. Arthritis Rheum 2005;52:1020-30. (Pubitemid 40530107)
93. Boers M. The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents. Ann Rheum Dis 2010;69:186-92.
94. Canadian Agency for Drugs and Technology in Health (CADTH), Therapeutic Review Panel. Biological response modifier agents for adults with rheumatoid arthritis. Ottawa: CADTH; July 2010. [Internet. Accessed June 9, 2011.] Available from: http://www.cadth.ca/en/search?q=biological+response
95. Fransen J, van Riel PL. Are better endpoints and better design of clinical trials needed? Best Pract Res Clin Rheumatol 2004;18:97-109. (Pubitemid 38324661)
96. US Department of Health and Human Services, Food and Drug Administration, Guidance for Industry: Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis. Rockville, MD: FDA; 1999.
97. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Evaluation of medicines for human use: points to consider on clinical investigation of medicinal products other than NSAIDS for treatment of rheumatoid arthritis. CPMP/EWP/556/95 rev 1/Final. London; 2003.
98. Yazici Y, Sokka T, Pincus T. Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009;35:723-9, vi.
99. Keystone EC. Clinical implications of understanding radiographic findings in relation to clinical outcomes in rheumatoid arthritis. J Rheumatol Suppl. 2009 June;82:11-6.
100. Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010;69:1298-304.
101. Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol 2009;28:749-56.
102. Day RO, Williams KM. Open-label extension studies: do they provide meaningful information on the safety of new drugs? Drug Saf 2007;30:93-105. (Pubitemid 46193061)
103. Treweek S, Pitkethly M, Cook J, Kjeldstrøm M, Taskila T, Johansen M, et al. Strategies to improve recruitment to randomised controlled trials. Cochrane Database Syst Rev 2010;4:MR000013.
104. Hemming K, Hutton JL, Maguire MJ, Marson AG. Open label extension studies and patient selection biases. J Eval Clin Pract 2008;14:141-4.
105. Grady C. The challenge of assuring continued post-trial access to beneficial treatment. Yale J Health Policy Law Ethics 2005;5:425-35.
106. Sofaer N, Thiessen C, Goold SD, Ballou J, Getz KA, Koski G, et al. Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study. J Med Ethics 2009;35:183-8.
107. Boers M. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? Arthritis Rheum 2003;48:1481-3. (Pubitemid 36682353)
108. Boers M. A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals. Ann Rheum Dis 2010;69:4-6.
109. Stein CM, Pincus T. Placebo-controlled studies in rheumatoid arthritis: ethical issues. Lancet 1999;353:400-3. (Pubitemid 29088179)
110. Kavanaugh A. Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64 Suppl 2:ii46-8. (Pubitemid 40288521)
111. Pincus T, Sokka T. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004;63 Suppl 2:ii32-ii39. (Pubitemid 39424656)
112. Rahman MU, Buchanan J, Doyle MK, Hsia E, Gathany T, Parasuraman S, et al. Historical trends of patient characteristics in anti-TNF clinical trials for rheumatoid arthritis: an analysis of the literature over the past 16 years [abstract]. Rome: EULAR Scientific Programme. EULAR 2010: SAT0131.
113. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313-8. (Pubitemid 36277997)
114. Bykerk V, Smuczek J, Boire G, Haraoui B, Hitchon C, Jamal S, et al. Early rheumatoid arthritis (ERA) trials have almost no generalizability to ERA patients: Results from a large multi-center cohort [abstract]. Arthritis Rheum 2008;58 Suppl:S161.
115. Yazici Y, Erkan D. Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus. Arthritis Rheum 2003;48:3611. (Pubitemid 37531930)
116. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54:3399-407. (Pubitemid 44737150)
117. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, De Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-8. (Pubitemid 350032655)
118. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003;30:1138-46. (Pubitemid 36666333)
119. Gogus F, Yazici Y, Yazici H. Inclusion criteria as widely used for rheumatoid arthritis clinical trials: patient eligibility in a Turkish cohort. Clin Exp Rheumatol 2005;23:681-4. (Pubitemid 41300712)